XML 16 R5.htm IDEA: XBRL DOCUMENT v3.8.0.1
Condensed Consolidated Statements of Cash Flows - USD ($)
9 Months Ended
Oct. 31, 2017
Oct. 31, 2016
Operating activities:    
Net loss $ (3,137,084) $ (4,142,381)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation 595,866 895,438
Amortization of capitalized software development costs 1,574,493 2,146,374
Amortization of intangible assets 922,462 976,338
Amortization of other deferred costs 229,780 192,947
Valuation adjustment for warrants liability 104,666 (36,875)
Share-based compensation expense 844,960 1,342,513
Other valuation adjustments 124,423 120,912
(Gain) loss on disposal of property and equipment (14,871) 567
Provision for accounts receivable 181,859 136,693
Changes in assets and liabilities, net of effects of acquisitions:    
Accounts and contract receivables 1,957,439 1,679,810
Other assets (671,254) 130,875
Accounts payable (308,747) (78,320)
Accrued expenses 134,324 (814,707)
Deferred revenues (3,866,878) (3,793,603)
Net cash used in operating activities (1,328,562) (1,243,419)
Investing activities:    
Purchases of property and equipment (24,517) (501,148)
Capitalization of software development costs (1,336,942) (1,420,678)
Payment for acquisition, net of cash received 0 (1,400,000)
Net cash used in investing activities (1,361,459) (3,321,826)
Financing activities:    
Principal repayments on term loan (962,443) (2,243,624)
Principal payments on capital lease obligation (91,337) (535,896)
Proceeds from exercise of stock options and stock purchase plan 23,703 14,793
Payments related to settlement of employee shared-based awards (41,813) (11,702)
Net cash used in financing activities (1,071,890) (2,776,429)
Net decrease in cash and cash equivalents (3,761,911) (7,341,674)
Cash and cash equivalents at beginning of period 5,654,093 9,882,136
Cash and cash equivalents at end of period $ 1,892,182 $ 2,540,462